Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (171-180 of 289) with videos related to

Pageof 29
Sort By:
Molecular Cancer Therapeutics|August 31, 2012
Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenograftsDavid E Gerber, Puja Gupta, Michael T Dellinger, et al.
Lung Cancer (Amsterdam, Netherlands)|January 27, 2022
Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNAThomas E Stinchcombe, Xiaofei Wang, Robert C Doebele, et al.
Cancer Immunology, Immunotherapy : CII|January 24, 2022
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitorsMitchell S von Itzstein, Amrit S Gonugunta, Yiqing Wang, et al.
Nature Communications|December 2, 2021
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoidsKe Gong, Gao Guo, Nicole A Beckley, et al.
JCO Clinical Cancer Informatics|May 5, 2025
Timing and Method of Patient-Provider Communication for Abnormal Hepatocellular Carcinoma Screening Results in CirrhosisJeremy Louissaint, Beverly Kyalwazi, John Deng, et al.
Healthcare (Amsterdam, Netherlands)|September 5, 2019
Stakeholder engagement to initiate lung cancer screening in an urban safety-net health systemSimon J Craddock Lee, Heidi A Hamann, Travis Browning, et al.
Medical Care|January 25, 2021
Reimbursement Matters: Overcoming Barriers to Clinical Trial AccrualSimon J Craddock Lee, Caitlin C Murphy, David E Gerber, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2013
Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancerHak Choy, Lee S Schwartzberg, Shaker R Dakhil, et al.
Cancer Immunology, Immunotherapy : CII|May 20, 2022
Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitorsMitchell S von Itzstein, Amrit S Gonugunta, Yiqing Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2015
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)Taofeek K Owonikoko, Suzanne E Dahlberg, Saad A Khan, et al.
Pageof 29

Showing results (171-180 of 289) with videos related to

Sort By:
Pageof 29
Molecular Cancer Therapeutics|August 31, 2012
Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenograftsDavid E Gerber, Puja Gupta, Michael T Dellinger, et al.
Lung Cancer (Amsterdam, Netherlands)|January 27, 2022
Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNAThomas E Stinchcombe, Xiaofei Wang, Robert C Doebele, et al.
Cancer Immunology, Immunotherapy : CII|January 24, 2022
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitorsMitchell S von Itzstein, Amrit S Gonugunta, Yiqing Wang, et al.
Nature Communications|December 2, 2021
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoidsKe Gong, Gao Guo, Nicole A Beckley, et al.
JCO Clinical Cancer Informatics|May 5, 2025
Timing and Method of Patient-Provider Communication for Abnormal Hepatocellular Carcinoma Screening Results in CirrhosisJeremy Louissaint, Beverly Kyalwazi, John Deng, et al.
Healthcare (Amsterdam, Netherlands)|September 5, 2019
Stakeholder engagement to initiate lung cancer screening in an urban safety-net health systemSimon J Craddock Lee, Heidi A Hamann, Travis Browning, et al.
Medical Care|January 25, 2021
Reimbursement Matters: Overcoming Barriers to Clinical Trial AccrualSimon J Craddock Lee, Caitlin C Murphy, David E Gerber, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2013
Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancerHak Choy, Lee S Schwartzberg, Shaker R Dakhil, et al.
Cancer Immunology, Immunotherapy : CII|May 20, 2022
Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitorsMitchell S von Itzstein, Amrit S Gonugunta, Yiqing Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2015
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)Taofeek K Owonikoko, Suzanne E Dahlberg, Saad A Khan, et al.
Pageof 29